Anyone who is at higher risk of thyroid cancer, for example with a personal or family history, should not take GLP-1 medications Loss of muscle
Its primary function is to trigger the pituitary gland to increase growth hormone
no human study has demonstrated an anti-fibrotic effect of systemic GHK-Cu, and the reconciliation of more collagen with less fibrosis remains a mechanistic argument rather than a measured clinical outcome
METHODS: The phase 3a, 68-week REDEFINE 1 trial randomized adults without diabetes with body mass index 30 kg/m 2 , or 27 kg/m 2 with 1 obesity-related complication, to once-weekly CagriSema 2.4 mg/2.4 mg, semaglutide 2.4 mg, cagrilintide 2.4 mg, or placebo, plus lifestyle intervention
GLP-1 Safety Data: What Recent Research Shows A retrospective analysis of 847 semaglutide users who contracted COVID-19 between 2021 and 2023 found no increased hospitalization rates compared to non-GLP-1 users with similar body weight and comorbidities
